Industry & Business

UCD Spin-out Secures €2.5 Million in Horizon 2020 SME Funding

 Breaking News
  • Aramark’s Frank Gleeson Named European Industry Leader of the Year Frank Gleeson, president of Aramark Northern Europe, has been named the 2018 NACS European Industry Leader of the Year. The award, sponsored by Mondelēz International, was presented during the recent NACS Convenience Summit Europe in London. “I cannot think of a better leader to be recognised for this prestigious award. He has been one of the industry’s strongest advocates for [...]...
  • McAleer & Rushe Recognised at the Irish Construction Industry Awards Gala Northern Ireland-based developer and contractor McAleer & Rushe has been awarded the prize for ‘International Project of the Year’ at the Irish Construction Industry Awards for Global Student Accommodation’s 1000-bed Catherine House scheme in Portsmouth. The awards, now in their fifth year, recognise companies which demonstrate excellence and innovation in Ireland’s construction industry. McAleer & [...]...
  • Bord Bia’s 2018 Brexit Barometer Results The Minister for Agriculture, Food and the Marine Michael Creed TD has launched the Bord Bia 2018 Brexit Barometer, a comprehensive survey of 117 Irish food, drink and horticulture companies, representing 48% of the sector’s exporters to the United Kingdom. Over 100 senior industry representatives attended the launch in Bord Bia to hear the report findings. The purpose [...]...
  • College Group to Construct New €10 Million Biofuel Facility in County Meath College Group is to invest €10 million in building a new renewable energy facility producing biofuel from used cooking oil and animal fats in north County Meath. The investment is supported by the Irish government through Enterprise Ireland. The new 25 million litre purpose-built plant will be set on a 47.5 acre site and will [...]...
  • Irish Global Packaging Solutions Company Announces €27 Million Investment Zeus, the Irish-owned global packaging solutions company, has announced a €27 million investment in new premises in Dublin and the UK. The investment will also lead to the creation of 80 jobs. An investment of €15 million will see Zeus’ Dublin presence double in size to 250,000 sq ft, with the creation of 50 new jobs. Zeus [...]...

UCD Spin-out Secures €2.5 Million in Horizon 2020 SME Funding

UCD Spin-out Secures €2.5 Million in Horizon 2020 SME Funding
May 28
10:37 2018

ATXA Therapeutics Ltd, a University College Dublin (UCD) life sciences spin-out, which is developing novel therapeutic drugs to treat pulmonary arterial hypertension (PAH), and other related cardiovascular conditions, has secured €2.5 million in funding under the European Union’s Horizon 2020 SME Instrument Programme Phase 2.

The company is one of just three Irish companies to secure funding in this latest round. Only 64 companies from across Europe, out of 1280 applications, were successful in securing funding in this scheme and were granted a total of €110 million.

ATXA Therapeutics was founded by Professor Therese Kinsella as a spin-out from the UCD School of Biomolecular and Biomedical Science at the UCD Conway Institute.

Pulmonary arterial hypertension (PAH) is a devastating disease of the lung and heart with an urgent unmet need for new improved therapies. While the condition itself is classed as a rare or orphan disease, affecting 15-50 patients per million of the population, it carries an enormous health burden with an annual spend of $6 billion globally on prescribed medicines alone.

ATXA has recently been awarded orphan designation from the European Medicines Agency and from the FDA for NTP42, its lead drug for PAH. Securing the Horizon 2020 SME Instrument Award will be a key accelerant in bringing ATXA’s NTP42 closer to the market by advancing the drug into clinical development.

Professor Therese Kinsella, founder and chief-scientific, ATXA.

Professor Therese Kinsella, founder and chief-scientific, ATXA, said: “This is a wonderful endorsement of ATXA’s overall mission and validation of its achievements to date.  We hope that this strong Europe-wide recognition of ATXA’s overall goal of bringing a new drug to the market for PAH will go a long way to bringing other investors on-board as part of its current fund-raise campaign.”

Tom Flanagan, UCD’s Director of Enterprise and Commercialisation, said: “This is a significant milestone which will enable the ATXA team to drive the company forward in its development of novel therapeutic drugs to treat pulmonary arterial hypertension. ATXA was one of only three Irish companies, out of 64 companies across Europe, to secure funding in this latest round which demonstrates the quality and global impact potential of the companies emerging from the world-class research programmes taking place at the University. UCD spin-outs have a strong track record in securing Horizon 2020 SME Instrument funding and today’s announcement builds on the previous success of companies such as OncoMark and SiriusXT.”

Carlos Moedas, EU Commissioner for Research, Science and Innovation, said: “Supporting innovation as a source of growth and job creation is at the core of the European Innovation Council. We support close-to-market projects, giving them a head start in the race to the market with a fast access to funding and business innovation support.”

The national support network for Horizon 2020, the EU’s programme for research and innovation, is funded by the Irish Government through Enterprise Ireland. From the programme’s inception in 2014 to January 2018, Ireland has secured over €513 million through Horizon 2020.

Imelda Lambkin, National Director for Horizon 2020 said: “Ireland’s highly innovative SMEs have a strong success rate in Europe for the Horizon 2020 SME Instrument and we are delighted that three more have won significant funding in this round. The success of Irish companies at a European level is built on Enterprise Ireland supports which aim to develop the innovative solutions and capability of SMEs to win Horizon 2020 funding.”

The other two Irish companies to receive Horizon 2020 SME Instrument Programme Phase 2 funding are AuriGen Medical and Metabolomic Diagnostics. In addition a fourth Irish company, Deciphex Ltd, will receive funding under the Fast Track to Innovation Scheme.

The European Commission will support a total of 79 innovative projects under the European Innovation Council (EIC) pilot to bring their innovations faster onto the market. In total, the projects are to receive just over €146 million under the SME Instrument (Phase 2) and Fast Track to Innovation strands of the EIC pilot.

About Author

admin

admin

Related Articles

New Subscriber





Subscribe Here



Advertisements



















National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4